Hadith Rastad1, Mahboubeh Parsaeian1, Nooshin Shirzad2,3, Mohammad Ali Mansournia1, Kamran Yazdani1. 1. 1Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, PO Box: 644614155, Tehran, Iran. 2. 2Department of Endocrinology, Vali Asr Hospital, Imam Khomeini Complex Hospital, Tehran University of Medical Sciences, Tehran, Iran. 3. 3Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Science Institute, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
PURPOSE: To assess the association between diabetes mellitus (DM) and the incidence of cancer at different sites. METHODS: Data from the baseline and first three follow-up visits of the Atherosclerosis Risk in Communities (ARIC) study, an ongoing cohort study of adults from four American communities, were used in this study. Of 15,792 persons aged 45-64 years old who participated in the baseline visit, the data of 15,118 participants were available for this study. For each cancer site, a conditional stratified Poisson regression model was fitted to estimate the adjusted relative rate and 95% confidence interval (adj. RR, 95% CI) of its incidence in diabetics compared to non-diabetics. RESULTS: We excluded 850 participants with a history of cancer at baseline and 149 participants who developed cancer during 2 years after enrollment, leaving a total of 14,119 participants of whom 1721 were diabetics. Independent of age, body mass index, alcohol consumption, and physical activity, DM decreased the risk of all cancers combined (adj. RR: 0.77, 95% CI: 0.60, 0.98) and the risk of prostate cancer (adj. RR: 0.51, 95% CI: 0.27, 0.97) and increased the risk of colorectal cancer in non-menopausal women (adj. RR: 12.08, 95% CI: 2.06, 70.94). CONCLUSIONS: In conclusion, DM may be associated with an increased risk of colorectal cancer in non-menopausal women and a decreased risk of prostate cancer and all cancers combined.
PURPOSE: To assess the association between diabetes mellitus (DM) and the incidence of cancer at different sites. METHODS: Data from the baseline and first three follow-up visits of the Atherosclerosis Risk in Communities (ARIC) study, an ongoing cohort study of adults from four American communities, were used in this study. Of 15,792 persons aged 45-64 years old who participated in the baseline visit, the data of 15,118 participants were available for this study. For each cancer site, a conditional stratified Poisson regression model was fitted to estimate the adjusted relative rate and 95% confidence interval (adj. RR, 95% CI) of its incidence in diabetics compared to non-diabetics. RESULTS: We excluded 850 participants with a history of cancer at baseline and 149 participants who developed cancer during 2 years after enrollment, leaving a total of 14,119 participants of whom 1721 were diabetics. Independent of age, body mass index, alcohol consumption, and physical activity, DM decreased the risk of all cancers combined (adj. RR: 0.77, 95% CI: 0.60, 0.98) and the risk of prostate cancer (adj. RR: 0.51, 95% CI: 0.27, 0.97) and increased the risk of colorectal cancer in non-menopausal women (adj. RR: 12.08, 95% CI: 2.06, 70.94). CONCLUSIONS: In conclusion, DM may be associated with an increased risk of colorectal cancer in non-menopausal women and a decreased risk of prostate cancer and all cancers combined.
Authors: Julius Gudmundsson; Patrick Sulem; Valgerdur Steinthorsdottir; Jon T Bergthorsson; Gudmar Thorleifsson; Andrei Manolescu; Thorunn Rafnar; Daniel Gudbjartsson; Bjarni A Agnarsson; Adam Baker; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Margret Jakobsdottir; Thorarinn Blondal; Simon N Stacey; Agnar Helgason; Steinunn Gunnarsdottir; Adalheidur Olafsdottir; Kari T Kristinsson; Birgitta Birgisdottir; Shyamali Ghosh; Steinunn Thorlacius; Dana Magnusdottir; Gerdur Stefansdottir; Kristleifur Kristjansson; Yu Bagger; Robert L Wilensky; Muredach P Reilly; Andrew D Morris; Charlotte H Kimber; Adebowale Adeyemo; Yuanxiu Chen; Jie Zhou; Wing-Yee So; Peter C Y Tong; Maggie C Y Ng; Torben Hansen; Gitte Andersen; Knut Borch-Johnsen; Torben Jorgensen; Alejandro Tres; Fernando Fuertes; Manuel Ruiz-Echarri; Laura Asin; Berta Saez; Erica van Boven; Siem Klaver; Dorine W Swinkels; Katja K Aben; Theresa Graif; John Cashy; Brian K Suarez; Onco van Vierssen Trip; Michael L Frigge; Carole Ober; Marten H Hofker; Cisca Wijmenga; Claus Christiansen; Daniel J Rader; Colin N A Palmer; Charles Rotimi; Juliana C N Chan; Oluf Pedersen; Gunnar Sigurdsson; Rafn Benediktsson; Eirikur Jonsson; Gudmundur V Einarsson; Jose I Mayordomo; William J Catalona; Lambertus A Kiemeney; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson Journal: Nat Genet Date: 2007-07-01 Impact factor: 38.330
Authors: Sonia Kelkar; Taofik Oyekunle; Adva Eisenberg; Lauren Howard; William J Aronson; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Zachary Klaassen; Martha K Terris; Stephen J Freedland; Ilona Csizmadi Journal: JNCI Cancer Spectr Date: 2021-03-09